OZMOSI’s predictions for where Alzheimer’s treatment is headed.

The Ravaging Effects of Alzheimer’s

The devastation of living with an Alzheimer’s diagnosis is exponentially affecting more and more people. A 2019 study conducted by The Lancet estimated 57 million people globally were living with dementia, with an expected increase to 153 million people by 2050, matching data published by Alzheimer’s Disease International (ADI) in the World Alzheimer Report 2019.  The authors of the Lancet study also state that dementia places disproportionate burdens on women, reflected in the ADI report on Women and Dementia in 2015.

Whether diagnosed with the disease or a caretaker to someone who is, the care and treatment of patients come at a steep cost to well-being and wallets. In 2019 the overall economic burden was measured to be an estimated $2.8 trillion globally – expected to reach $16.9 trillion in less than three decades.

The Most Recent Treatment Developments

Statistics like these demonstrate that it is imperative an effective treatment be introduced and approved soon for this growing patient population. A good deal of focus recently has been on two monoclonal antibodies by Eisai and Biogen, both of which are AB Degraders that reduce the buildup of amyloid plaques in the brain that are characteristic of the disease’s progression.

The first, aducanumab (Biogen – BIIB), generated controversy when it was greenlighted by the Food and Drug Administration (FDA) but had marginal cognitive benefits coupled with a very high price tag. The second, lecanemab (Biogen – BIIB, Eisai – ESALY), has been granted priority review by the FDA, and is differentiated from aducanumab in that it doesn’t require incremental dosing and can be started immediately at the highest dose.

The Timing and Impact of Treatment

To date, these types of treatments targeting the reduction of amyloid plaque have produced only marginal cognitive benefits in the treatment of Alzheimer’s.  There is a school of thought emerging that perhaps we should treat the amyloid plaque before the cognitive symptoms occur, similar to how we treat high cholesterol as a risk factor for heart disease.

A neuroscientist at Harvard University, Rudolph E. Tanzi, suggests plaque-targeting treatment should start in the earliest stages because by the time cognitive decline kicks in, it may be too late. If we look to how the medical and public perceptions of heart disease and early treatment shifted between 1970 and 2000, we could learn quite a few lessons.

Through improved screening for high-risk patients with hypertension and high cholesterol during this period, associated mortality rates declined by approximately 60% in the US and Canada. If treating physicians and the pharmaceutical industry address Alzheimer’s the same way as coronary heart disease, treatments could start much sooner and, therefore, have a much greater impact.

What We Can and Should Do

What if we included an amyloid-beta blood test or PET scan as part of recommended screenings along with mammograms and colonoscopies in people who are 50 and older? Physicians could identify those patients at risk and who would benefit from preventative treatment long before cognitive symptoms occur.

If this approach became standard, the number of people with Alzheimer’s in the future could possibly be half of what is currently projected, driving tremendous savings in the healthcare systems and, more importantly, increasing the quality of life for millions of potential patients and their families.

What this means for the pharmaceutical companies could be huge as well. Currently, a few companies are already pursuing this bold new treatment approach in their clinical study designs. Eisai/Biogen (BIIB/ESALY), Eli Lilly (LLY), and Roche (RHHBY) all have studies underway to include people at risk (i.e., with high amyloid measures before any significant behavioral symptoms), and as a result, these companies could find themselves in one of the biggest pharmaceutical markets to date.

Under this new treatment paradigm, the Alzheimer’s treatment population would increase from patients with Alzheimer’s symptoms to everyone at risk for Alzheimer’s.  Additionally, this population would be taking the medicine for longer than the original forecasts projected because patients could start treatment as much as 10 years ahead of when Alzheimer’s symptoms would have started, giving these people a greater likelihood of living longer because of the medication.

How We Use BEAM to Understand the Market Landscape

We created this graphic using BEAM, our clinical trial tracking and reporting tool that captures trends and categories through intuitive visuals and dynamic views. This landscape view highlights the twelve companies with clinical investment in AB Degraders for the treatment of Alzheimer’s. Each circle represents a clinical trial, blue for active trials and gray for completed trials. The companies at the front of the pack in the prevention of Alzheimer’s are Biogen/Eisai (AHEAD), Elli Lilly (Trailblazer-ALZ3), and Roche (SKYLINE)

Alzheimer’s

Implications of this New Treatment Paradigm on Product Forecasts

Our preliminary analysis shows that the early entrants in this market are likely almost double the initial (and already very large) forecasts for Alzheimer’s. However, like the heart disease example given earlier, this opens the door for many more players to enter or re-enter this market.

Market Dynamics Expected with this New Treatment Paradigm

Currently, there are five companies in active clinical development with AB Degraders and another seven with clinical experience that we might see reignited based on the results of the ongoing trials for the prevention of Alzheimer’s. While these latecomers won’t enjoy the same benefits that the early pioneers Eisai/Biogen, Eli Lilly, and Roche have, there will be a significant market available to later entrants as well. The dynamics of the market are likely to be similar to the statin market, crowded but with each new entrant bringing differentiating factors, combination therapies, and competition for pricing – all of which should drive positive results overall for patients, their families, and the healthcare system.

 

Not Your Grandparents’ Probability of Success Forecasts

Redefining Probability of Success in Pharma: A Data-Driven Revolution In the world of pharmaceutical strategic planning and analytics, traditional Probability of Success (POS) forecasts are a familiar, yet often frustrating approach to assessing clinical risk. While...

Clinical Trial Success Rates: What Makes Some Companies Stand Out?

Our comprehensive analysis of over 30,000 clinical trials across more than 4,000 biopharmaceutical companies reveals significant variations in clinical trial success rates. This disparity exists even among trials in the same phase and targeting the same disease,...

Healthiest States Index of The USA 2024

Health and wellness are pivotal for leading a wholesome life. Good health is a blessing. Time and health are the two most precious assets for human beings. Good health provides better possibilities for us to overcome challenges in life and reap its benefits.  Do you...

FDA Accelerated Approval, Breakthrough Therapy, and Fast Track Designations Supercharge Drug Development

FDA Expedited Drug Development Programs The Food and Drug Administration (FDA) follows an established and lengthy approval process that ensures patients have access to therapeutic agents proven to be safe and effective. The process relies upon a structured framework...

Finding the Needle in a Haystack with NLP

The problem with Big Data is that it is so Big!  This issue is especially true in the world of healthcare and drug development.  It is difficult to see across all the good clinical/scientific work going on around the world and understand exactly where we are headed...

China Reshaping the Clinical Trial Pipeline

Finally, the data is in here at OZMOSI, and we can start tracking and reporting on the clinical development expected to come out of China.  Gone are the days of developing drugs only in the US and then watching them slowly make their way to the rest of the world....

Using Data to Optimize Clinical Trial Recruitment

The Importance of a High-Performing Clinical Trial Partnership Pharmaceutical companies are heavily dependent on clinical trials to assist with the placement, promotion, and sales of their products. If they are introducing a new mechanism of action (MOA) or modality...

Uncovering New Catalyst Events in the Pharmaceutical and Biotech Markets

The Challenges with Predicting Catalyst Events “Chasing headlines” for catalyst events in the biotech and pharmaceutical markets is a common frustration of investing in these spaces. Predicting these headlines in advance is a primary goal, along with mastering the...

The Clinical Trial Powershift

Pharmaceutical companies are being pushed aside when it comes to who is driving clinical outcomes. Despite the growing number of industry trials year over year, the pharmaceutical industry is taking a back seat to the even faster growing hospital groups and...

The Future of Innovation in Diabetes & Heart Disease

When it comes to improving the lives of patients with chronic illnesses like type-2 diabetes and heart disease, the pharmaceutical industry is playing an ever smaller role.  New blockbuster drugs are the lifeblood of pharmaceutical companies.  Traditionally, they...